IL-SEVAN
11.5.2022 15:02:07 CEST | Business Wire | Press release
Sevan Multi-Site Solutions, Inc. (Sevan) has officially launched a new website , which offers a clean, modern design with all new content highlighting the company’s turnkey program management solutions.
Sevan—a global leader in innovative program management solutions for clients with multiple sites—redesigned the company’s website to provide clients, partners and all visitors an engaging user experience via informative resources. The website dives into Sevan’s wide-ranging services focused on restaurant, retail and government sectors.
“We are thrilled to launch our new website and strongly believe it will serve as an informative space for visitors to learn about Sevan’s full suite of offerings,” said Jim Evans, Founder and CEO. “The new website accurately represents our exceptional organization and culture, and properly aligns with our company vision for growth and expansion. I’m confident our great current and future clients will enjoy the updated, resourceful web tool!”
The new website showcases what Sevan does, how it’s done and how the team delivers excellence for clients across the world. The site features enhanced navigation and brand-new content including case studies, program success stats, blogs, whitepapers, videos and photos featuring the Sevan team, client and team testimonials, project heat maps and more.
“We are all very excited about Sevan’s new website, which highlights the exceptional work Sevan does and how fantastic our colleagues are,” said David Hendrix, Chief Commercial Officer. “The new website is bold and beautiful—and reinforces Sevan as an industry thought leader in the multi-site program management space.”
Sevan invites visitors to explore the new website to learn more about how Sevan guides global, iconic brands consistently produce fast, data-driven and customized multi-site solutions while putting their capital to work.
In 2021, Sevan was recognized as an Employee-Rated Great Place to Work® for the 8th consecutive year and ranked on the Inc. 5000 list of the nation’s fastest-growing private companies for the 4th consecutive year. Also in 2021, Sevan ranked No. 21 on Engineering News-Record (ENR)’s Top 50 Program Management Firms, No. 44 on ENR’s Top 100 Construction Management-for-Fee Firms and earned the Gold HIRE Vets Medallion Award. In 2020, Sevan ranked No. 124 on the Financial Times FT 1000 list of America’s Fastest-Growing Companies. Visit our website to learn more about Sevan.
About Sevan
Sevan helps iconic, global brands optimize their multi-site construction and facility programs in the U.S. and internationally. Sevan is headquartered near Chicago in Downers Grove, Illinois, with 400+ employees and has an international office in London.
The vision of Sevan Multi-Site Solutions is to be the best in the world at delivering innovative design, program management, construction services and data analytics to organizations with multiple sites. Sevan has a passion for sustaining people, the environment and its clients’ businesses. Sevan strategically guides iconic brands—including 7-Eleven, AAFES, Albertsons, Amtrak, BP, Carbon Health, Chipotle, Corvias, DaVita, Focus Brands, HCA Healthcare, HEB, Inspire Brands, Jiffy Lube, Kroger, Luxottica, McDonald’s, Motor Fuel Group, Office Depot, Popeyes, QDOBA, Starbucks, Sunoco, Walgreens Boots Alliance, Walmart, WOW Carwash and Yum! Brands—through their entire turnkey program lifecycle. Sevan rolls out multi-site initiatives efficiently, predictably and transparently. Applying breakthrough technology solutions, Sevan optimizes construction of new builds, rebuilds, remodels and renovations. Sevan has licensed architects in 49 states as well as D.C., Canadian provinces, Guam and the Northern Mariana Islands. Sevan has professional engineers on staff and general contractor licenses in more than 25 states. Since Sevan’s inception in 2011, the team has refreshed more than 25,000 retail stores, 17,000 restaurants and 32,000 healthcare sites. The team has also completed more than 32,000 surveys, totaling more than 1 billion square feet. Sevan Elevate, a program that reinforces and continuously improves safety and sustainability across the company, is designed to impactfully deliver excellence to Sevan’s people and clients. To read more about Sevan, visit www.sevansolutions.com .
For more information, please contact Hafsa Mahmood by calling 312.285.0590 or via e-mail at hafsa.mahmood@sevansolutions.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510006438/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM and Deutsche Bahn Demonstrate Quantum Algorithm for Railway Scheduling on Real Operational Data20.7.2026 08:00:00 CEST | Press release
A hybrid quantum-classical algorithm, executed end to end on IQM hardware, produced feasible schedules with Deutsche Bahn, the German rail operator, using a real operational dataset of 190 trips across five German cities. The approach runs on today’s hardware and is designed to improve automatically as quantum processors scale, offering enterprises a model for extracting value now, ahead of fault-tolerant computing. The collaboration reflects IQM’s push into enterprise adoption. The company has sold 24 quantum computers worldwide and listed on the Nasdaq Global Select Market and Nasdaq Helsinki in July 2026 under the ticker IQMX. IQM Quantum Computers (Nasdaq: IQMX), a global leader in full-stack superconducting quantum computers, today published the results of a research collaboration with Deutsche Bahn, Europe’s largest rail operator, exploring how quantum computing can improve railway scheduling. This press release features multimedia. View the full release here: https://www.busines
Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region20.7.2026 07:00:00 CEST | Press release
Galderma launches Alastin, its premium regenerative skincare brand into Japan, Singapore, South Korea and Taiwan The Japan and Asia Pacific (JPAC) region is among the fastest‑growing markets globally for medical aesthetics and dermatological skincare, driven by rising adoption of minimally invasive procedures and an increased focus on skin quality, which are accelerating demand for innovative, science‑based skincare solutions such as Alastin1,2 These launches reflect Galderma’s ongoing growth across the JPAC region and long‑term commitment to advancing regenerative skincare Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC region. The brand recently launched in Taiwan, will soon launch in Japan, and has received approval to launch in Singapore and South Korea, with planned market introduction in September and November, respectively. This expansion follows Alastin’s recent la
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 19:10:00 CEST | Press release
Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic ca
STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 14:24:00 CEST | Press release
STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom